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Abstract
Background: Studies have shown that the immunosuppression induced by the human immunodeficiency virus
(HIV) accelerates the natural history of liver disease associated with hepatitis C virus (HCV), with 3- to 5-fold higher
odds of coinfected individuals developing cirrhosis. However, estimates of the seroprevalence of hepatitis C among
people living with HIV/acquired immune deficiency syndrome (AIDS) (PLHA) in Latin America and the Caribbean
(LAC) are widely variable.
Methods: We performed a systematic review to estimate the seroprevalence of HCV among PLHA. We searched
studies on HIV and HCV infections in LAC included in the PubMed, LILACS and Embase databases in December of
2014 with no time or language restrictions. The following combinations of search terms were used in the PubMed
and Embase databases: (HIV OR Acquired Immunodeficiency Syndrome Virus OR AIDS OR HTLV OR Human
Immunodeficiency Virus OR Human T Cell) AND (HCV OR HEPATITIS C OR HEPATITIS C VIRUS OR HEPACIVIRUS) AND
(name of an individual country or territory in LAC). The following search terms were used in the LILACS database: (HIV
OR AIDS OR Virus da Imunodeficiencia Humana) AND (HCV OR Hepatite C OR Hepacivirus). An additional 11 studies
were identified through manual searches. A total of 2,380 publications were located, including 617 duplicates; the
remaining articles were reviewed to select studies for inclusion in this study.
Results: A total of 37 studies were selected for systematic review, including 23 from Brazil, 5 from Argentina, 3 from
Cuba, 1 from Puerto Rico, 1 from Chile, 1 from Colombia, 1 from Mexico, 1 from Peru and 1 from Venezuela. The
estimated seroprevalence of HCV infection varied from 0.8 to 58.5 % (mean 17.37; median 10.91), with the highest in
Argentina and Brazil and the lowest in Venezuela and Colombia.
Conclusions: Investigation of HCV infection among PLHA and of HIV infection among people living with HCV is highly
recommended because it allows for better follow up, counseling and treatment of HIV/HCV-coinfected patients. Future
studies with larger sample sizes are needed in both South and Central America to understand and address the risk
factors associated with the acquisition of infection.
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Background
Approximately 2.2 to 3.0 % of the world’s population
(130–170 million people) is infected with the hepatitis C
virus C (HCV), and approximately 36.7 million people live
with human immunodeficiency virus infection/acquired
immune deficiency syndrome (HIV/AIDS) [1, 2]. The oc-
currence of coinfection has been reported because HCV
and HIV share the same transmission mechanisms.
Although HIV/HCV-coinfected individuals do not seem
to have an increased risk of AIDS, kidney disease or heart
disease, their odds of developing cirrhosis are higher [3].
HCV infection increases the number of deaths due to liver
disease among coinfected individuals but does not influ-
ence the virological or immunological responses to highly
active antiretroviral therapy (HAART) [4].
There is evidence that HIV may negatively influence the
progression of HCV-related liver disease. According to
one meta-analysis [5], the prevalences of cirrhosis in pop-
ulations of HIV-infected individuals 20 and 30 years after
HCV infection were 21 % (95 % CI: 16–28 %) and 49 %
(95 % CI: 40–59 %), respectively. Other studies [6, 7]
found that HIV-induced immunosuppression accelerated
the natural history of HCV-related liver disease and that
the odds of coinfected patients developing cirrhosis were
3- to 5-fold higher.
Additionally, the odds of hepatotoxicity due to HAART
are higher among HIV/HCV coinfected patients than in
individuals with HIV monoinfection [8].
In contrast to the situation in Europe and the United
States, few data are available concerning HCV/HIV coin-
fection in Latin America and the Caribbean (LAC) des-
pite their relevance for the formulation of public health
policies. The aim of the present study was to investigate
the seroprevalence of HCV infection among people liv-
ing with HIV/AIDS (PLHA) in LAC.
Methods
We performed a systematic review of published studies
on the seroprevalence of HCV infection among PLHA
in countries and/or territories in LAC. The review was
performed and described following the “PRISMA” (Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analysis) Statement published in 2009 [9].
Search strategies
We searched all studies on HIV and HCV infection in
LAC included in the PubMed, LILACS (Literatura Latino-
Americana e do Caribe em Ciências da Saúde/Latin
American and Caribbean Health Sciences Literature) and
Embase databases in December of 2014 with no time or
language restrictions. The following combinations of
search terms were used in the PubMed and Embase data-
bases: (HIV OR Acquired Immunodeficiency Syndrome
Virus OR AIDS OR HTLV OR Human Immunodeficiency
Virus OR Human T Cell) AND (HCV OR HEPATITIS C
OR HEPATITIS C VIRUS OR HEPACIVIRUS) AND
(name of an individual country or territory in LAC). The
following search terms were used in the LILACS database:
(HIV OR AIDS OR Virus da Imunodeficiencia Humana)
AND (HCV OR Hepatite C OR Hepacivirus). The key-
words were used as “text” (all fields) in the databases. We
performed a manual search of the references cited in the
selected studies and review articles to detect additional
relevant publications. All instances of disagreement in the
identification of relevant publications were discussed until
a consensus was reached. To achieve this consensus, the
researchers responsible for each phase review spoke either
in person or by phone to present their arguments. If the
disagreement persisted, the references in question were
selected for the next phase of the study.
The titles and abstracts of the located publications
were independently analyzed by 2 examiners (KYI and
BPD), resulting in a list of potentially relevant studies.
The full texts of these articles were analyzed for inclu-
sion in the systematic review.
Articles describing data on HIV/HCV coinfection with
a serologic diagnosis of HIV and HCV infection that re-
ported estimates of the prevalence of anti-HIV/anti-
HCV antibodies among HIV-infected individuals were
included in the review.
Study selection
We included original articles reporting the seroprevalence
of antibodies against HCV (anti-HCV) among PLHA in
LAC in the review provided that the number of participants
was 50 or larger. We did not include case reports, case
series, review articles, comments, or studies whose partici-
pants did not reside in LAC or had been described in previ-
ous publications. In the case of multiple studies performed
on the same population, only the most complete data were
included in the study. We also excluded self-reported HIV
and/or HCV infection, data resulting from mandatory
reporting of HIV and/or HCV infection (e.g., databases of
national health ministries), specific groups of PLHA (e.g.,
drug users and homeless) and data from clinical trial or
therapeutic studies.
The following definitions were used in the present re-
view: (1) HIV infection: presence of anti-HIV antibodies
based on immunoenzymatic methods; (2) HCV infection:
presence of anti-HCV antibodies based on the immu-
noenzymatic method or immunoblotting; and (3) LAC:
the following countries and territories - Argentina, Bolivia,
Brazil, Chile, Colombia, Ecuador, French Guiana, Guyana,
Paraguay, Peru, Suriname, Uruguay, Venezuela, Belize,
Costa Rica, El Salvador, Guatemala, Honduras, Mexico,
Nicaragua, Panama, Aruba, Antigua and Barbuda, Aruba,
Bahamas, Barbados, Bonaire, British Virgin Islands,
Cayman Islands, Cuba, Curaçao, Dominica, Dominican
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Republic, Grenada, Guadalupe, Haiti, Jamaica, Martinique,
Montserrat, Puerto Rico, Saba, Saint Barthélemy, Saint
Kitts and Nevis, Saint Lucia, Saint Martin, Saint Vincent
and the Grenadines, Sint Eustatius, Sint Maarten, Trinidad
and Tobago, Turks and Caicos Islands and the United
States Virgin Islands.
Data extraction
The data were independently collected by 2 examiners
(MCM and CM); instances of disagreement were solved
by discussion and consensus. The following data were
extracted from the selected articles: author, year of pub-
lication, country, period of data collection, type of study,
investigated population, sample size, average age, partici-
pants’ genders, seroprevalence of HCV, and method used
to establish the hepatitis C diagnosis.
Some articles did not report all of the seroprevalence-
related variables; in these cases, the missing data were
calculated based on the reported values (e.g., the numer-
ator was calculated from the reported denominator and
seroprevalence).
Assessment of the quality of the studies
Based on the criteria formulated by Boyle [10], Fowkes
& Fulton [11], Loney [12] and Prins [13], we elaborated
a list of criteria to assess the adequacy of the following
aspects: sampling (11 items: study design, prospective
data collection, definition of the target population, prob-
abilistic sampling, sample size calculation, inclusion and
exclusion criteria, specified data collection period, speci-
fied age variation, participant selection, acceptable losses,
and representative sample), data collection (4 items: stan-
dardized data collection, clear defined outcomes, clear de-
scription of the outcome detection method, and valid
method for outcome diagnosis), and data analysis and de-
scription (6 items: description of statistical analysis, total
number of participants, number of events (outcome),
prevalence by age and gender, prevalence including confi-
dence intervals, and satisfactory confidence intervals). The
total number of items was 21. The items were scored as
positive or negative without relevance weighting. Larger
scores (positive responses) corresponded to studies with
better quality relative to the aims of the present review.
The quality of the studies was independently assessed by 2
examiners (KYI and BPD).
Results
A total of 2,369 articles was located in the investigated da-
tabases (PubMed, LILACS and Embase), and an additional
11 articles were identified through a manual search of the
references cited in the selected studies and review articles
(Fig. 1). Following the exclusion of duplicates (617), 1,753
articles remained for the abstract analysis. Review of the
abstracts led to the exclusion of 1,668 articles. Thus, 95 ar-
ticles were selected for the full-text analysis, of which 37
(n = 21,383 individuals) published from 1992 to 2014 were
included in the systematic review.
Among these 37 studies on the seroprevalence of
HCV infection among PLHA [14–50], 23 studies were
conducted in Brazil, 5 in Argentina, 3 in Cuba, 1 in
Puerto Rico, 1 in Chile, 1 in Colombia, 1 in Mexico, 1 in
Peru and 1 in Venezuela (Table 1). The sample size
Fig. 1 Flowchart of the identification, inclusion, and exclusion of the studies
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varied from 60 to 2,994. Prospective data collection was
performed in 16 studies (43.24 %). Diagnosis of HCV in-
fection was established based on anti-HCV antibody de-
tection using enzyme-linked immunosorbent assay
(ELISA) 3 in 15 studies (40.54 %), ELISA2 in 3 studies
(8.11 %), ELISA1 in 1 study (2.70 %) and (unspecified)
ELISA in 18 studies (48.69 %). The average quality score
was 10.76 (variation: 4–18), with 7 studies scoring 7
points or less, 26 scoring 8 to 14 points and 4 scoring 15
to 21 points. The most common cause of impaired
Table 1 Seroprevalence studies of hepatitis C virus (HCV) in people living with HIV/AIDS in Latin America and the Caribbean
Author Year Location Gender Mean age
(years)
Data
collection
Sample
size
Anti-HCV detection
N (%)
ELISA kit
generation
Freitas [14] 2014 BRAZIL M/F 41.6 P 848 59 (7.0 %) NA
Librelotto [15] 2014 BRAZIL M/F 41.9 R 148 16 (10.8 %) NA
Jaspe [16] 2014 VENEZUELA M/F NA R 418 3 (0.7 %) 3th generation
Simon [17] 2014 BRAZIL M/F 40.6 P 580 138 (23.8 %) 3th generation
Távora [18] 2013 BRAZIL M/F NA R 329 23 (7.0 %) NA
Brunetta [19] 2013 BRAZIL M/F NA R 701 146 (20.8 %) NA
Farias [20] 2013 ARGENTINA M/F 39.2 R 238 62 (26.0 %) NA
Oliveira-Filho [21] 2012 BRAZIL M/F 38.1 R 768 52 (6.8 %) 3th generation
Victoria [22] 2010 BRAZIL M/F 38.5 R 1,582 70 (4.4 %) NA
Wolff [23] 2010 BRAZIL M/F 40.3 R 1,143 357 (31.2 %) 3th generation
Guimarães [24] 2010 BRAZIL M/F 41.6 R 110 10 (9.1 %) 3th generation
Santos [25] 2010 BRAZIL M/F 33.8 R 250 78 (31.2 %) NA
Perez [26] 2010 PUERTO RICO M/F NA P 1,650 86 (5.2 %) NA
Sampaio [27] 2009 BRAZIL M/F 39.3 P 429 46 (10.7 %) 3th generation
Pérez [28] 2009 CHILE M/F 40.9 R 273 7 (2.6 %) NA
Carvalho [29] 2009 BRAZIL M/F NA P 343 14 (4.1 %) 3th generation
Ré [30] 2008 ARGENTINA M/F NA P 310 39 (12.6 %) NA
Carmo [31] 2008 BRAZIL M/F NA R 824 76 (9.2 %) 3th generation
Reiche [32] 2008 BRAZIL M/F NA P 757 159 (21.0 %) NA
dos Santos [33] 2008 BRAZIL M/F NA P 299 10 (3.3 %) 3th generation
Alfonso [34] 2008 CUBA M/F NA R 90 18 (20.0 %) NA
Mussi [35] 2007 BRAZIL M/F 37.2 P 1,008 110 (10.9 %) NA
Quarleri [36] 2007 ARGENTINA M/F 39 P 593 129 (21.8 %) 3th generation
Rivas-Estilla [37] 2007 MEXICO M/F 34 P 140 17 (12.1 %) 3th generation
Hoyos-Orrego [38] 2006 COLOMBIA M/F 37.9 P 251 2 (0.8 %) 2th generation
Tovo [39] 2006 BRAZIL M/F 34.4 R 330 126 (38.2 %) 3th generation
de Carvalho [40] 2006 BRAZIL M/F NA P 343 14 (4.1 %) 3th generation
Bello Corredor [41] 2005 CUBA NA NA R 2,994 314 (10.4 %) NA
Rodriguez [42] 2005 CUBA F 29 R 60 5 (8.4 %) NA
de los Angeles Pando [43] 2004 ARGENTINA M/F 36.7 R 165 53 (30.5 %) 3th generation
Segurado [44] 2004 BRAZIL M/F NA P 495 179 (36.2 %) 3th generation
Pavan [45] 2003 BRAZIL M/F 30.8 P 232 119 (53.8 %) 2th generation
Mendes-Corrêa [46] 2001 BRAZIL M/F 34.08 R 1,457 258 (17.7 %) 2th generation
Treitinger [47] 1999 BRAZIL NA NA R 93 50 (53.8 %) NA
Fainboim [48] 1999 ARGENTINA M/F 29 P 484 283 (58.5 %) NA
Edelenyi-Pinto [49] 1993 BRAZIL M/F NA R 187 28 (15.0 %) 1th generation
Hyams [50] 1992 PERU M/F NA R 305 13 (4.3 %) NA
M male, F female, P prospective, R retrospective, NA not available
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quality scores was the methods used for sampling (more
detailed data on the assessment of the quality of studies
are available in the Additional files 1 and 2).
The estimated seroprevalence of HCV infection in the
37 selected studies from the LAC region varied from 0.7
to 58.5 % (mean 17.4; median 10.9) (Table 1). The high-
est prevalence was found in studies from Argentina and
Brazil and the lowest from Venezuela and Colombia
(Table 2).
Most of the selected studies were performed in Brazil.
Figure 2 shows the geographic distribution of PLHA
coinfected with HCV in Brazil described in these studies.
Notably, the southern region had 30 % of all cases [15,
17, 23, 25, 32, 39, 47], followed by the southeast (25.4 %)
[19, 24, 44–46, 49] and midwest (8.9 %) [14, 35] regions
(Fig. 2).
Discussion
HCV infection is a significant cause of increased mor-
bidity and mortality among individuals living with HIV/
AIDS and other populations of immunodeficient pa-
tients as a whole. If we consider that 1 out of 10 individ-
uals living with HIV/AIDS also has hepatitis C, there are
175,000 HIV/HCV coinfected individuals in LAC (based
on 1,750,000 individuals living with HIV/AIDS). By sum-
marizing the results of several studies, we attempted to
present a comprehensive summary of the literature on
the subject and to gain a new understanding of the dis-
tribution of anti-HCV among PLHA.
Our systematic review of the prevalence of hepatitis C
among individuals living with HIV/AIDS included re-
ports from 37 studies corresponding to 21,383 partici-
pants residing in the LAC region. Our main findings
included the wide heterogeneity in the information con-
cerning the subject of interest, with the relevant studies
conducted in only 9 countries, most of which were in
South America. Our review showed that the mean LAC
regional seroprevalence of hepatitis C among PLHA was
approximately 17.4 %. The substantial heterogeneity ob-
served in our study suggests that caution is required
when pooled estimates are used. Because an error can
occur in the estimated prevalence when attempting to
perform a meta-analysis of very heterogeneous data, a
meta-analysis was not performed. Additionally, our find-
ings emphasize the need for surveys to include careful
descriptions of the sampling procedures and diagnostic
methods.
We were not able to locate any review studies on the
seroprevalence of hepatitis C among PLHA specifically
in the LAC region. In a large cohort of primarily Euro-
pean HIV-infected individuals, Rockstroh et al. found
that 33 % of the patients also exhibited HCV infection.
Approximately 25 % of the participants were injection
drug users (IDUs). The proportion of IDUs among indi-
viduals with hepatitis C was 77.5 %. In one study con-
ducted in HIV-infected patients in the United States
[51], 16 % of the sample also exhibited HCV infection.
Approximately 20 % of the participants were IDUs, of
which 72.7 % were HCV-positive. In one study per-
formed in Russia, 91 % of HIV-infected IDUs exhibited
anti-HCV antibodies [52]. Similarly, high rates of HIV/
HCV coinfection were found in the United States [53],
Australia [54], India [55], northern Vietnam [56] and
some regions in China [57, 58]. In the Swiss HIV Cohort
Study, the prevalences of HIV/HCV coinfection among
IDUs and homosexual and heterosexual men were 87.7,
3.7 and 6 %, respectively [59]. An association between
drug use and HIV/HCV coinfection was reported in sev-
eral studies [51, 59, 60].
One possible cause for the heterogeneity in the sero-
prevalence results extracted from the selected studies may
be differences in the proportion of IDUs included in the
studies; we could not analyze this factor with the available
data. According to Nelson et al. [61], the prevalence of
HCV infection among IDUs in Latin America is approxi-
mately 67 %, with a range from 10 to 97 %. These authors
collected data corresponding to 5 countries [Argentina
(54.6 %), Brazil (63.9 %), Mexico (97.4 %), Paraguay (9.8 %)
and Uruguay (21.9 %)] but were unable to locate suffi-
cient information to estimate the HCV prevalence in
the Caribbean.
The seroprevalence results reported in the studies se-
lected in this systematic review may also be attributed to
the different prevalence rates of HCV among the overall
population in the locations where the studies were con-
ducted. It is possible to speculate that the HCV preva-
lence in target populations (here, PLHA) is higher in
locations where the prevalence of HCV among the over-
all population is also higher, although not all studies se-
lected for this review support this hypothesis. This
possibility is a cause for concern because the seropreva-
lence data included in our review do not include the
Table 2 Seroprevalence of HCV infection in the general
population and PLHA by country
Country Seroprevalence of HCV in
general population [1, 63] (%)
Seroprevalencea of HCV
in HIV patients (%)
Argentina 1.9 29.9
Brazil 1.4 18.9
Chile 0.8 2.6
Colombia 1.0 0.8
Cuba 1.8 12.9
Mexico 1.0 12.1
Peru 1.0 4.3
Puerto Rico 6.3 5.2
Venezuela 0.9 0.7
aMean seroprevalence found in the selected studies
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locations with the highest hepatitis C prevalence in the
LAC region, such as Bolivia (4.7 %) and Haiti (4.4 %) [1].
The use of an ELISA method for anti-HCV detection
was considered appropriate, but differences in the sero-
prevalence might be due to the kit used to establish the
hepatitis C diagnosis because the tests might present cer-
tain differences in sensitivity and specificity. The third- or
fourth-generation immunoenzymatic assays are considered
better because they contain HCV core antigens and HCV
nonstructural genes [62]. Therefore, third- and fourth-
generation ELISAs are more specific diagnostic tech-
niques. When these methods are used, the rate of positive
results is lower than that obtained with older methods
(first- and second-generation ELISAs).
The seroprevalence of HCV among PLHA seems to be
higher than that in the overall population. This finding sug-
gests that preventive measures targeting the overall popula-
tion do not reduce the prevalence of HCV or HIV in the
previously infected population (HIV or HCV). More direct
comparisons should be performed with studies using the
same sampling methods and techniques to establish the
diagnosis of hepatitis C in both the overall population and
the population of HIV-seropositive individuals.
A limitation of the present study is that the data col-
lection was quite heterogeneous. Most studies used con-
venience samples, which may not be representative of
the population of individuals living with HIV/AIDS.
Additionally, we did not analyze the studies per country
or territory because they were only conducted in 9 coun-
tries (6 in South America, 2 in Central America and 1 in
North America).
Conclusions
The high mean seroprevalence found in the LAC region
(17.4 %) reinforced the recommendation that investiga-
tions of HCV infection among PLHA and of HIV in-
fection among individuals with hepatitis C are highly
recommended to allow for better follow up, counseling
and treatment of HIV/HCV-coinfected patients. Future
studies with larger sample sizes are needed in both South
and Central America to understand and address the risk
factors associated with the acquisition of infection.
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